Overview

• Milestone Q3 2025 reports no revenue, net loss of $11.9 mln

• Company prepares for CARDAMYST launch pending FDA approval in December

• Milestone strengthens finances with equity offering and royalty agreement

Outlook

• Milestone plans quick launch of CARDAMYST following potential FDA approval

• Company expects $75 mln royalty payment upon CARDAMYST FDA approval

• Milestone poised to enter Phase 3 program for etripamil in AFib-RVR

Result Drivers

• COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray

• FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch

• CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91

Press Release: ID:nGNX9WQQF4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)